B4GALNT2: A Potential Drug Target and Biomarker (G124872)

Target Name: B4GALNT2

NCBI ID: G124872

B4GALNT2

Other Name(s): B4GALNT2 variant 1 | UDP-GalNAc:Neu5Acalpha2-3Galbeta-R beta1,4-N-acetylgalactosaminyltransferase | Beta-1,4-N-acetyl-galactosaminyltransferase 2, transcript variant 1 | beta-1,4-N-acetyl-galactosaminyl transferase 2 | B4GN2_HUMAN | Beta-1,4 N-acetylgalactosaminyltransferase 2 (isoform b) | beta-4-N-acetylgalactosaminyltransferase | UDP-GalNAc:Neu5Aca2-3Galb-R b1,4-N-acetylgalactosaminyltransferase | Sda beta-1,4-GalNAc transferase | beta-1,4 N-acetylgalactosaminyltransferase 2 | sda beta-1,4-GalNAc transferase | Sd(a) beta-1,4-GalNAc transferase | B4GALT | GALGT2 | Beta-1,4-N-acetyl-galactosaminyltransferase 2, transcript variant 2 | beta-1,4-N-acetyl-galactosaminyltransferase 2 | beta 1,4 N-acetylgalactosaminyltransferase/betal,4 GalNAcT/Sda-GalNAcT | sd(a) beta-1,4-GalNAc transferase | Beta-1,4 N-acetylgalactosaminyltransferase 2 | B4GALNT2 variant 2 | Beta-1,4 N-acetylgalactosaminyltransferase 2 (isoform a)

B4GALNT2: A Potential Drug Target and Biomarker

B4GALNT2 is a gene that encodes a protein involved in the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The protein has been shown to be involved in the development and progression of these disorders, which makes it a promising target for drug development. In this article, we will discuss the potential of B4GALNT2 as a drug target and biomarker.

Potential Drug Target

B4GALNT2 has been shown to play a role in the development and progression of neurological disorders, which makes it a potential drug target. The protein has been shown to be involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease, and in the destruction of neurotransmitter-producing neurons, which is a hallmark of Parkinson's disease.

In addition, B4GALNT2 has been shown to interact with dopamine, a neurotransmitter that is involved in mood, motivation, and pleasure. This suggests that B4GALNT2 may be involved in the treatment of disorders that are characterized by disrupted dopamine signaling, such as Parkinson's disease.

B4GALNT2 as a Biomarker

B4GALNT2 has also been shown to be a potential biomarker for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The protein has been shown to be involved in the development and progression of these disorders, which makes it a potential indicator of the severity and progression of these conditions.

In addition, B4GALNT2 has been shown to be involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. This suggests that B4GALNT2 may be a useful biomarker for the treatment of Alzheimer's disease, as targeting the protein may be a way to reduce the formation of beta-amyloid plaques and slow the progression of the disease.

Conclusion

In conclusion, B4GALNT2 is a protein that has been shown to be involved in the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The protein has also been shown to be involved in the formation of beta-amyloid plaques, which are a hallmark of these disorders. These findings suggest that B4GALNT2 may be a promising drug target and biomarker for the treatment of these disorders. Further research is needed to confirm these findings and to develop safe and effective treatments for B4GALNT2-related disorders.

Protein Name: Beta-1,4-N-acetyl-galactosaminyltransferase 2

Functions: Involved in the synthesis of the Sd(a) antigen (Sia-alpha2,3-[GalNAc-beta1,4]Gal-beta1,4-GlcNAc), a carbohydrate determinant expressed on erythrocytes, the colonic mucosa and other tissues. Transfers a beta-1,4-linked GalNAc to the galactose residue of an alpha-2,3-sialylated chain

The "B4GALNT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B4GALNT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets